Related Experiment Video

Updated: Jan 31, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients

Lingjuan Ruan1, Lifei Huang2, Lilai Zhao3

  • 1Department of Laboratory, People's Hospital of Anji, Huzhou, Zhejiang 313300, China.

Gastroenterology Research and Practice
|January 10, 2019
PubMed

Insights

Hepatitis B virus infection increases risk for liver cirrhosis and cancer. Long noncoding RNAs (lncRNAs) lncRNA-HEIH and lncRNA-HULC, along with HBXIP protein, are upregulated in patients and interact, suggesting a role in disease progression.

Area of Science:

  • Molecular biology
  • Hepatology
  • Oncology

Background:

  • Hepatitis B virus (HBV) infection is a primary cause of liver cirrhosis (HC) and hepatocellular carcinoma (HCC), leading to significant global morbidity and mortality.
  • Long noncoding RNAs (lncRNAs), specifically lncRNA-HEIH (highly expressed in HCC) and lncRNA-HULC (highly upregulated in liver cancer), are implicated in the pathogenesis of HBV-related HC and HCC.

Purpose of the Study:

  • To investigate the expression levels of lncRNA-HEIH, lncRNA-HULC, and hepatitis B X-interacting protein (HBXIP) in hepatitis B patients.
  • To determine the interaction between HBXIP and the identified lncRNAs in the context of HBV-related liver diseases.

Main Methods:

  • Reverse transcription and quantitative PCR (RT-qPCR) were employed to quantify the expression of lncRNA-HEIH and lncRNA-HULC.
  • Western blot analysis was utilized to assess the protein expression levels of HBXIP.
  • RNA immunoprecipitation (RIP) assays were performed to confirm the physical interaction between HBXIP and lncRNA-HULC/lncRNA-HEIH.

Main Results:

  • Expression of lncRNA-HEIH, lncRNA-HULC, and HBXIP was found to be elevated in hepatitis B patients.
  • Upregulation of these molecules was particularly pronounced in patients with hepatitis B-related HCC.
  • Interaction between HBXIP and both lncRNA-HEIH and lncRNA-HULC was experimentally confirmed.

Conclusions:

  • lncRNA-HEIH, lncRNA-HULC, and HBXIP are upregulated in hepatitis B patients, especially those with HCC.
  • These lncRNAs physically interact with HBXIP.
  • The findings suggest a significant role for the lncRNA-HEIH/lncRNA-HULC-HBXIP complex in the development and progression of hepatitis B-related liver diseases.

More Related Videos

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

277
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
274
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
243
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
572